A 41-year-old woman received a syngeneic BMT for CLL and subsequently developed acute skin GVHD. Transfusion-related allogeneic GVHD was excluded on the basis of an unchanged HLA type in circulating lymphocytes. Short tandem repeat PCR was used to confirm syngeneicity between donor and recipient. The patient had a personal and family history of autoimmune disease which may have made her particularly susceptible to development of syngeneic GVHD. The distinction between allogeneic and syngeneic or autologous GVHD is important because of therapeutic implications. Keywords: GVHD; syngeneic BMT; CLL; chimerism We report the case of a 41-year-old woman who received a syngeneic BMT for CLL and subsequently developed histologically proven acute grade 2 skin GVHD requiring treatment, including high-dose corticosteroids. The HLA type of circulating lymphocytes remained unchanged. Short tandem repeat (STR)-PCR analysis of pre-BMT DNA extracted from donor and recipient indicated identity between donor and recipient supporting the diagnosis of syngeneic GVHD. Syngeneic and autologous GVHD has been described in animal models. 1,2 Mild and self-limiting acute skin GVHD is thought to occur in 8% of patients receiving autologous and syngeneic BMT. 
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Case report
The patient presented with stage B CLL and Sjogren's syndrome in 1992. There was a strong family history of autoimmune disease. The patient, her mother and identical twin sister all had hypothyroidism and the patient's mother also had SLE. The patient required intermittent treatment for CLL but, by 1994, her disease had advanced to cause bone marrow failure. She showed a good response to six courses of fludarabine with a reduction in bone marrow lymphocytic infiltration to 40%. She subsequently received a syngeneic BMT following CY 120 mg/kg and single fraction TBI (750 cGy at 16 cGy/min) conditioning. Both recipent and donor were CMV seronegative. At the time of transplant, the patient had no evidence of active autoimmune disease. She received irradiated blood products throughout. The transplant was uncomplicated with haemopoietic recovery (Ͼ0.5 × 10 9 /l neutrophils, Ͼ20 × 10 9 /l platelets) at day 25. Over the next week she developed a generalised skin rash which progressed to desquamation. She was systemically well with no evidence of infection. She had not been commenced on any new drugs in the preceding 3 weeks. A skin biopsy showed the appearances of grade II GVHD with basal cell degeneration and a focal lymphocytic infiltration of the epidermis (Figure 1 ). Although the patient had been designated to receive irradiated blood products, and showed no deterioration in bone marrow function, we felt that transfusion acquired GVHD should be excluded because of therapeutic implications. The HLA type of the circulating lymphocytes was determined and was unchanged. Pre-BMT DNA extracted from the recipient and donor was compared using a panel of STR markers as previously described. 4 Seven markers were tested (see Table 1 ) and all gave identical profiles between donor and recipient. Examples of the STR-PCR analysis are shown in Figure 2 . The highly informative nature of the STR markers used and the identical pattern seen with all markers tested indicates that the donor and recipient were syngeneic. There was no evidence of gut or liver GVHD. The patient was treated with high-dose steroids, methyl prednisolone 10 mg/kg/day. Because of stabilisation but lack of improvement, CYA and then thalidomide were added, which enabled weaning of the steroid dose. The skin rash gradually improved enabling CYA and thalidomide to be discontinued by week 13. A skin biopsy on week 17 showed appearances of mild GVHD. A bone marrow on week 19 was normocellular with no evidence of CLL on immunophenotyping. A PCR assay on the bone marrow for the original clonal IgH gene rearrangement was negative at 18 months. The patient remains well with no evidence of CLL or GVHD at 30 months follow-up. 
Discussion
In this report, the use of STR-PCR confirmed the syngeneic nature of the transplant. Acute skin GVHD is described in the context of autologous and syngeneic BMT. 3, [5] [6] [7] [8] [9] [10] The mechanism is thought to be release of autoreactive T cells directed at HLA class II antigens 2, 11, 12 by failure of apoptotic deletion due to thymic damage by TBI. 13, 14 This mechanism may be enhanced by CYA which breaks selftolerance 15 and has been used to induce autologous GVHD. 13, 16, 17 The role of TBI in inducing autologous GVHD is supported in a recent report of a patient who developed GVHD after a second syngeneic transplant with TBI conditioning but not after an initial transplant without conditioning. 9 Involvement of the skin in acute GVHD is thought to be related to expression of HLA class II antigens on Langerhans cells 18 and induction of these antigens on keratinocytes by lymphokine recruitment. 19, 20 Our patient may have been particularly vulnerable to development of GVHD in view of the family history of autoimmunity and a possible propensity to generation of autoreactive T cells in the donor marrow, possibly exacerbated by prior use of fludarabine, which might mimic the effects of TBI. 9 The potential association of autologous GVHD with a graft-versus-leukaemia (GVL) or lymphoma effect is clearly of major interest, particularly in HLA class II expressing diseases. Induction of autologous GVHD by CYA has been demonstrated in clinical studies but no correlation with improved survival has been established. 12, 16, 17, 21 In animal models, there is some evidence that these effects are separable. 22, 23 We have recently demonstrated induction of autologous GVL in AML in the absence of GVHD. 24 It is important for clinicians and histopathologists to be aware of and recognise autologous GVHD. Histological comparison with other skin eruptions which may develop after bone marrow transplantation is described. 25 Discrimination between autologous GVHD and allogeneic or transfusion-associated GVHD is crucial as the former is usually a benign and self-limiting condition whereas transfusionassociated GVHD is almost uniformly lethal. In the case reported, the use of a mini-satellite DNA PCR assay confirmed syngenicity and therapy could be modified in that context. Active treatment to suppress the reaction was considered appropriate in the short-term to limit further lymphokine-mediated recruitment of HLA class II antigen expression and long-term skin damage.
